ABN AMRO Bank N.V. Lowers Stock Holdings in Medtronic PLC $MDT

ABN AMRO Bank N.V. cut its holdings in Medtronic PLC (NYSE:MDT) by 32.8% in the 1st quarter, HoldingsChannel reports. The fund owned 55,306 shares of the medical technology company’s stock after selling 27,000 shares during the period. ABN AMRO Bank N.V.’s holdings in Medtronic were worth $4,840,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Curbstone Financial Management Corp increased its stake in shares of Medtronic by 1.8% during the 4th quarter. Curbstone Financial Management Corp now owns 5,594 shares of the medical technology company’s stock valued at $537,000 after acquiring an additional 100 shares during the last quarter. New England Capital Financial Advisors LLC boosted its holdings in Medtronic by 7.8% in the fourth quarter. New England Capital Financial Advisors LLC now owns 1,403 shares of the medical technology company’s stock valued at $135,000 after acquiring an additional 101 shares during the last quarter. Ipsen Advisor Group LLC grew its position in Medtronic by 1.7% during the fourth quarter. Ipsen Advisor Group LLC now owns 5,952 shares of the medical technology company’s stock valued at $572,000 after acquiring an additional 101 shares during the period. Quadrant Capital Group LLC increased its stake in Medtronic by 0.3% during the fourth quarter. Quadrant Capital Group LLC now owns 32,477 shares of the medical technology company’s stock worth $3,120,000 after acquiring an additional 101 shares during the last quarter. Finally, Baker Tilly Wealth Management LLC increased its stake in Medtronic by 3.3% during the fourth quarter. Baker Tilly Wealth Management LLC now owns 3,221 shares of the medical technology company’s stock worth $309,000 after acquiring an additional 102 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Price Performance

MDT opened at $80.94 on Friday. Medtronic PLC has a twelve month low of $73.31 and a twelve month high of $106.33. The firm has a market cap of $103.60 billion, a price-to-earnings ratio of 21.70, a PEG ratio of 2.17 and a beta of 0.58. The company has a current ratio of 2.13, a quick ratio of 1.87 and a debt-to-equity ratio of 0.52. The company has a fifty day simple moving average of $79.39 and a 200 day simple moving average of $89.74.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. The firm had revenue of $9.81 billion for the quarter, compared to analyst estimates of $9.62 billion. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The firm’s revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.62 EPS. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Equities research analysts expect that Medtronic PLC will post 5.94 EPS for the current fiscal year.

Medtronic Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 17th. Stockholders of record on Friday, June 26th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, June 26th. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.6%. Medtronic’s dividend payout ratio is presently 76.14%.

Insider Activity at Medtronic

In related news, EVP Harry Skip Kiil sold 4,189 shares of the business’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the transaction, the executive vice president owned 37,227 shares in the company, valued at approximately $2,994,539.88. The trade was a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.26% of the company’s stock.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Analysts highlighted Medtronic’s positioning in cardiac ablation, diabetes care, and hypertension treatment, including progress with its FDA-approved Symplicity Spyral renal denervation system, which supports the long-term growth story. How Investors May Respond To Medtronic (MDT) Optimism On Renal Denervation Amid Mixed Quantitative Signals
• Positive Sentiment: Medtronic shares have also benefited recently from broad interest around its medical device pipeline and relatively steady operating performance, helping offset some short-term caution.
• Neutral Sentiment: Unusually high options volume suggests traders are positioning for a larger move in MDT, but the direction is not definitive on its own.
• Negative Sentiment: CEO Geoffrey Martha said tariff costs are now expected to total about $250 million in fiscal 2027, which is still a meaningful headwind despite being lower than the prior $300 million estimate. Medtronic plc (MDT) CEO Discloses the Impacts of Tariffs on the Company
• Negative Sentiment: Heavy put buying — about 25,075 contracts, well above normal levels — points to bearish sentiment and concern that the shares could weaken further.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on MDT. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $118.00 price objective on shares of Medtronic in a research note on Thursday, June 4th. Barclays increased their target price on shares of Medtronic from $118.00 to $120.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 1st. Citigroup cut their price target on shares of Medtronic from $117.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Wells Fargo & Company cut their price target on shares of Medtronic from $114.00 to $102.00 and set an “overweight” rating on the stock in a report on Thursday, June 4th. Finally, Mizuho reduced their price target on shares of Medtronic from $120.00 to $100.00 and set an “outperform” rating on the stock in a research report on Wednesday, June 3rd. Seventeen research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Medtronic has a consensus rating of “Moderate Buy” and an average price target of $99.00.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).